Cordyceps Sunshine Biotech Holdings (RAJAF) EPS (Weighted Average and Diluted) (2021 - 2023)

Cordyceps Sunshine Biotech Holdings' EPS (Weighted Average and Diluted) history runs 3 years deep, the most recent figure standing at $0.01 for Q4 2023.

• In Q4 2023, EPS (Weighted Average and Diluted) rose 442.37% year-over-year to $0.01; the TTM figure through Dec 2024 stood at -$0.0 (up 54.92% YoY), while the FY2025 annual figure was -$0.0, up 31.57% from the prior year.
• EPS (Weighted Average and Diluted) was $0.01 for Q4 2023 at Cordyceps Sunshine Biotech Holdings, up from -$0.0 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.01 in Q4 2023 to a low of -$3.72 in Q4 2021.
• Historically, EPS (Weighted Average and Diluted) has averaged -$1.24 across 3 years, with a median of -$0.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) surged 99.92% in 2022, then soared 442.37% in 2023.
• A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$3.72 in 2021, then soared by 99.92% to -$0.0 in 2022, then jumped by 442.37% to $0.01 in 2023.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.01 (Q4 2023), -$0.0 (Q4 2022), and -$3.72 (Q4 2021), per Business Quant data.